Bio-Rad Laboratories Inc
Company Profile
Business description
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
Contact
1000 Alfred Nobel Drive
HerculesCA94547
USAT: +1 510 724-7000
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
31 December 2025
Employees
7,700
Stocks News & Analysis
stocks
Picking dividend shares in 2026? Here’s where to look
stocks
Ahead of earnings, is Nvidia a buy, a sell, or fairly valued?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,834.00 | 88.40 | 1.01% |
| CAC 40 | 7,981.07 | 27.30 | 0.34% |
| DAX 40 | 23,278.85 | 115.93 | 0.50% |
| Dow JONES (US) | 45,795.95 | 342.82 | -0.74% |
| FTSE 100 | 9,527.65 | 20.24 | 0.21% |
| HKSE | 25,835.57 | 4.92 | 0.02% |
| NASDAQ | 22,218.67 | 345.56 | -1.53% |
| Nikkei 225 | 49,823.94 | 1,286.24 | 2.65% |
| NZX 50 Index | 13,439.40 | 112.50 | 0.84% |
| S&P 500 | 6,567.28 | 74.88 | -1.13% |
| S&P/ASX 200 | 8,552.70 | 84.70 | 1.00% |
| SSE Composite Index | 3,931.05 | 15.69 | -0.40% |